Biocorrx INC 10-Q quarterly reports

BioCorRx Inc. filed its Q2 2026 Form 10-Q, revealing a 50.6% year-over-year revenue decrease and continued net losses, while also highlighting progress in its pharmaceutical subsidiary's research.

BioCorRx Inc. reported a 59% increase in revenue for Q1 2026, driven by Lucemyra sales, but continued to incur net losses.

BioCorRx Inc. reported a significant revenue increase in Q3 2025, driven by the Lucemyra acquisition, despite ongoing net losses and a substantial working capital deficit, raising going concern doubts.

BioCorRx Inc. reported a significant revenue increase driven by a new acquisition but continues to face substantial doubt about its ability to continue as a going concern, compounded by a new legal challenge to its grant funding.

BioCorRx Inc. reports a significant revenue increase in Q1 2025 driven by the acquisition of Lucemyra, despite ongoing concerns about its ability to continue as a going concern.

BioCorRx Inc. reports a net loss for the third quarter of 2024, with ongoing research and development efforts and financial restructuring activities.

BioCorRx Inc. reported a significant decrease in revenue for the second quarter of 2024, coupled with increased operating expenses, leading to a larger net loss compared to the same period last year.

BioCorRx Inc. reported its first quarter 2024 financial results, showing a decrease in revenue and an increase in net loss, while continuing to advance its addiction treatment solutions and pharmaceutical development.